MedTrace Logo

Expanding the Click City Tobacco Prevention Program to Include E-cigarettes and Other Novel Tobacco Products

NCT03682900 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2673

Last updated 2023-11-01

Study results available
· View outcomes & findings →

Summary

The goal of this study is to modify a smoking prevention program for 5th and 6th grade students to also target vaping e-cigarettes. Aims were to modify the program along with associated materials and to conduct a trial with 5th grade students in the school setting to see how well the updated program worked. Students either participated in the four-week computer based program or continued with their usual tobacco prevention curriculum.

This study showed that students who received the computer program reduced their intentions and willingness to use e-cigarettes or smoke in the future more than did students who used their usual tobacco curriculum.

Conditions

  • Tobacco Use

Interventions

OTHER

Click City®: Tobacco

A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.

OTHER

Usual Tobacco Curriculum

Students complete their usual curriculum designed to prevent tobacco use.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Oregon Research Behavioral Intervention Strategies, Inc.

    lead INDUSTRY

Principal Investigators

  • Judy A Andrews, PhD · Oregon Research Behavioral Intervention Strategies, Inc.

  • Judith S. Gordon, PhD · University of Arizon

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-06-15
Completion
2022-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03682900 on ClinicalTrials.gov